MEDSIR & Debiopharm announce the first patient dosed in the WIN-B trial exploring the combination of Debio 0123 & Gilead’s Trodelvy in advanced breast cancer

CAR-T Digest - August 2020

Weekly Digest - February 2025

25 Feb 2025: MEDSIR & Debiopharm announce the first patient dosed in the WIN-B trial exploring the combination of Debio 0123 & Gilead’s Trodelvy in advanced breast cancer

Debiopharm and MEDSIR have announced the dosing of the first patient in the WIN-B clinical trial evaluating the combination of Debio 0123 and Trodelvy in advanced or metastatic breast cancers
Debio 0123 is a brain-penetrant, selective WEE1 kinase inhibitor, while Trodelvy is a Trop-2-directed ADC approved for metastatic triple-negative and HR+/HER2- breast cancer in multiple countries
Preclinical studies presented at AACR 2024 demonstrated promising anti-tumor activity of Debio 0123 in combination with Trodelvy in breast cancer models
The Debio 0123 and Trodelvy combination is still under investigation and has not been approved by any regulatory authority
The trial is sponsored by MEDSIR, fully funded by Debiopharm, and supported by Gilead, which is providing the supply of Trodelvy